Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies-Reference-Cited by-同舟云学术

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies

Published:2019-05 Issue: Volume:30 Page:236-243
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Mayer Lori,Kappos Ludwig^ORCID,Racke Michael K.^ORCID,Rammohan Kottil,Traboulsee Anthony^ORCID,Hauser Stephen L.,Julian Laura,Köndgen Harold,Li Carrie,Napieralski Julie,Zheng Hanzhe,Wolinsky Jerry S.

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference23 articles.

1. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre;Brown;Drug Saf.,2011

2. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL;Calabresi;Neurology,2007

3. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial;Cohen;Lancet,2012

4. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial;Coles;Lancet,2012

5. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol;Conte;Mult. Scler. Relat. Disord.,2019

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-09-10

2. ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation;PharmacoEconomics - Open;2024-07-11

3. Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system;Frontiers in Neurology;2024-06-27

4. Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration;Open Forum Infectious Diseases;2024-05-25

5. ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial;Journal of Neurology;2024-04-22